Urogen Pharma Ltd is a biotechnology company focused on developing and commercializing innovative therapies for treating uro-oncological diseases. The company specializes in the research and development of novel drug formulations that target bladder cancer and other urological conditions, aiming to address significant unmet medical needs. With a commitment to advancing patient care, Urogen leverages its proprietary technology platforms to create transformative treatment options that enhance patient outcomes and improve the quality of life for individuals affected by these serious conditions. Read More
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit. Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen and certain of UroGen’s top current and former executives with violations of the Securities Exchange Act of 1934.
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ:URGN) securities during the period from July 27, 2023, through May 15, 2025 (“the Class Period”). Investors have until July 28, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025. UroGen engages in the development and commercialization of solutions for specialty cancers. The Company’s lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. (“UroGen” or “the Company”) (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws.
Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) and reminds investors of the July 28, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). UroGen investors have until July 28, 2025 to file a lead plaintiff motion.
The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Cockrell v. UroGen Pharma Ltd., et al., Case No. 3:25-cv-06088, on behalf of persons and entities that purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Cockrell v. UroGen Pharma Ltd., et al., Case No. 3:25-cv-06088, on behalf of persons and entities that purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA to take place on May 27-28, 2025.
NEW YORK, NY - May 24, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).
NEW YORK, NY - May 24, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).
NEW YORK, NY - May 23, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).
NEW YORK, NY - May 22, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
UroGen shares traded lower Wednesday after the ODAC of the Food and Drug Administration voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution.
UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced the outcome of today’s meeting of the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA), which discussed the new drug application (NDA) for investigational drug UGN-102 (mitomycin) for intravesical solution. By a narrow margin, the ODAC voted 4 to 5 that the benefit/risk of UGN-102 (mitomycin) for intravesical solution was favorable for the treatment of recurrent LG-IR-NMIBC.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) investors concerning the Company’s possible violations of the federal securities laws.
